Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Sanofi Sets Sights on 2026 NIP Inclusion of RSV Drug Beyfortus in Japan
Sanofi is aiming to secure national immunization program (NIP) status in Japan for its anti-respiratory syncytial virus (RSV) antibody Beyfortus (nirsevimab) as early as 2026, a move the company says would make the preventive drug accessible to all newborns and…
To read the full story
Related Article
- Japan Eyes Early FY2027 Rollout of RSV Antibodies under NIP: Minister
July 21, 2026
- Immunization Act Revision Faces Uncertain Fate as Diet Clock Ticks Down
July 13, 2026
- Lower House Clears Immunization Act Revision
July 1, 2026
- Japan Diet Begins Deliberations on Immunization Act Revision
June 25, 2026
- Cabinet Approves Immunization Act Revision to Cover Antibody Drugs
June 10, 2026
- LDP Panel OKs Immunization Act Bill Aimed at Beyfortus NIP Use
May 27, 2026
- MHLW Moves Toward Immunization Act Revision for RSV Antibody Drugs
May 21, 2026
- Sanofi Eyes Double-Digit Annual Growth for Japan Vaccine Business: Exec
May 20, 2026
- Japan Eyes June Submission of Immunization Act Bill to Cover Antibody Drugs
May 18, 2026
- Panel Backs Proposal to Allow Antibody Drugs Like Beyfortus in NIP
May 1, 2026
- Japan Starts Review on Scope of Drugs Eligible for Immunization Use, with Beyfortus in Focus
January 23, 2026
- Sanofi to Take Over Japan MA for Beyfortus from AstraZeneca
July 22, 2025
- Sanofi Launches Epidemiological Study for Beyfortus in Japan
April 7, 2025
- Susaki City to Subsidize Beyfortus Use in Healthy Babies
April 3, 2025
- Sanofi Stages V-Shaped Recovery in Vaccine Biz, Set for Growth with New Products Beyond Hib
January 27, 2025
- Japan to Prepare Fact Sheets on RSV Vaccine, Antibody
September 5, 2024
BUSINESS
- Kaken’s Vascular Malformation Drug Shows Efficacy in Japan PIII
July 21, 2026
- J&J’s Carvykti Wins Japan Approval for Earlier-Line MM Use
July 21, 2026
- Merck Biopharma Starts Japan PIII Trial of LH/FSH Combo
July 17, 2026
- Eisai’s Dayvigo Accepted for EMA Review
July 17, 2026
- AbbVie Files Maviret for Acute Hepatitis C
July 17, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…